STX-1200 A preclinical X-Editor gene-editing therapy targeting LPA to durably lower lipoprotein(a) in patients with genetically elevated cardiovascular risk.
Visit productCosigns Received
Be the first Cosign
Put your name behind STX-1200.
Add it to your Products I use list and share why you use it.